Clinical manifestation and natural history of diabetic nephropathy

Contributions to Nephrology

Volumn 170, Issue , 2011, Pages 19-27

  Ritz, Eberhard ^a   Zeng, Xiao Xi ^b   Rychlík, Ivan ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SICHUAN UNIVERSITY   (China)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 84925956145     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000324939     Document Type: Article

References (50)

1. Ardalan MR, Shoja MM, Tubbs RS, Eknoyan G: Diseases of the kidney in medieval Persia -The Hidayat of Al-Akawayni. Nephrol Dial Transplant 2007;22:3413-3121.
2. Ritz E, Rychlík I, Locatelli F, Halimi S: Endstage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808. (Pubitemid 29521694)
3. van Dieren S, Uiterwaal CS, van der Schouw YT, et al: The global burden of diabetes and its complications: An emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010;17(suppl 1):S3-S8.
4. Tang SC: Diabetic nephropathy: A global and growing threat. Hong Kong Med J 2010;16: 244-245.
5. Williams ME: Diabetic CKD/ESRD 2010: A progress report? Semin Dial 2010;23:129-33.
6. Rychlik I, Miltenberger-Miltenyi G, Ritz E: The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol Dial Transpl 1998;13(suppl 8):6-10. (Pubitemid 28532587)
7. Yokoyama H, Okudaira M, Otani T, et al: Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in earlyonset diabetes in Japan. Kidney Int 2000;58: 302-311. (Pubitemid 30429875)
8. Atkins RC, Zimmet P: Diabetic kidney disease: Act now or pay later. J Am Soc Hypertens 2010;4:3-6.
9. Zoccali C, Kramer AK, Jager K: The databases: Renal replacement therapy since 1989 -the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA). Clin J Am Soc Nephrol 2009;4(suppl 1):S18-S22.
10. Burrows NR, Li Y, Geiss LS: Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 2009;33:73-77.
11. James MT, Hemmelgarn BR, Tonelli M: Early recognition and prevention of chronic kidney disease. Lancet 2010;375:1296-1309.
12. Plantinga LC, Crews DC, Coresh J, et al: Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010;5: 673-682.
13. Schwenger V, Müssig C, Hergesell O, Zeier M, Ritz E: Incidence and clinical characteristics of renal insufficiency in diabetic patients (in German). Dtsch Med Wochenschr 2001;126:1322-1326. (Pubitemid 33116423)
14. Kovesdy CP, Park JC, Kalantar-Zadeh K: Glycemic control and burnt-out diabetes in ESRD. Semin Dial 2010;23:148-156.
15. Randhawa G: Renal health disparities in the United Kingdom: A focus on ethnicity. Semin Nephrol 2010;30:8-11.
16. Feehally J: Ethnicity and renal replacement therapy. Blood Purif 2010;29:125-129.
17. Kao TW, Huang JW, Hung KY, et al: Life expectancy, expected years of life lost and survival of hemodialysis and peritoneal dialysis patients. J Nephrol 2010;23:677-682.
18. Kalantar-Zadeh K, Golan E, Shohat T, et al: Survival disparities within American and Israeli dialysis populations: Learning from similarities and distinctions across race and ethnicity. Semin Dial 2010;23:586-594.
19. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al: Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004;27:195-200. (Pubitemid 38196732)
20. Retnakaran R, Cull CA, Thorne KI, et al: Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832-1839. (Pubitemid 44324140)
21. Uzu T, Kida Y, Shirahashi N, et al: Cerebral microvascular disease predicts renal failure in type 2 diabetes. J Am Soc Nephrol 2010;21:520-526.
22. Myers DI, Poole LJ, Iman K, et al: Renal artery stenosis by three-dimensional magnetic resonance angiography in type 2 diabetics with uncontrolled hypertension and chronic renal insufficiency: Prevalence and effect on renal function. Am J Kidney Dis 2003;41:351-359. (Pubitemid 36152453)
23. Ishani A, Xue JL, Himmelfarb J, et al: Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009;20:223-228.
24. Stolker JM, McCullough PA, Rao S, et al: Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. J Am Coll Cardiol 2010;55:1433-1440.
25. Singh P, Rifkin DE, Blantz RC: Chronic kidney disease: An inherent risk factor for acute kidney injury? Clin J Am Soc Nephrol 2010;5:1690-1695.
26. Christensen PK, Larsen S, Horn T, et al: Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int 2000;58:1719-1731.
27. Chavers BM, Mauer SM, Ramsay RC, Steffes MW: Relationship between retinal and glomerular lesions in IDDM patients. Diabetes 1994;43:441-446. (Pubitemid 24064253)
28. Pham TT, Sim JJ, Kujubu DA, et al: Prevalence of nondiabetic renal disease in diabetic patients. Am J Nephrol 2007;27: 322-328. (Pubitemid 47164683)
29. Heine GH, Sester U, Girndt M, Köhler H: Acanthocytes in the urine: Useful tool to differentiate diabetic nephropathy from glomerulonephritis? Diabetes Care 2004;27:190-194. (Pubitemid 38196731)
30. Mazzucco G, Bertani T, Fortunato M, et al: Different patterns of renal damage in type 2 diabetes mellitus: A multicentric study on 393 biopsies. Am J Kidney Dis 2002;39:713-720. (Pubitemid 34263344)
31. Barnett AH, Bain SC, Bouter P, et al: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-1961. (Pubitemid 39447136)
32. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;352:851-860.
33. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
34. Hallan SI, Ritz E, Lydersen S, et al: Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009;20:1069-1077.
35. Ruggenenti P, Fassi A, Ilieva AP, et al: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951. (Pubitemid 39447135)
36. Atkins RC, Briganti EM, Lewis JB, et al: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281-287. (Pubitemid 40431053)
37. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87. (Pubitemid 32661190)
38. Appel LJ, Wright JT Jr, Greene T, et al: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363:918-929.
39. Kamoi K, Miyakoshi M, Soda S, et al: Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. Diabetes Care 2002;25:2218-2223. (Pubitemid 41071031)
40. Adler AI, Stratton IM, Neil HA, et al: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000;321:412-419. (Pubitemid 30609443)
41. Mancia G, Laurent S, Agabiti-Rosei E, et al: Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158.
42. de Galan BE, Perkovic V, Ninomiya T, et al: Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-892.
43. PohlMA, Blumenthal S, Cordonnier DJ, et al: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J Am Soc Nephrol 2005;16:3027-3037. (Pubitemid 44743500)
44. Sleight P Redon J, Verdecchia P, et al: Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009;27:1360-1369.
45. Gong Q, Gregg EW, Wang J, et al: Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: The China Da Qing Diabetes Prevention Outcome Study. Diabetologia 2011:54:300-307.
46. Selvin E, Steffes MW, Zhu H, et al: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-811.
47. Mac-Moune Lai F, Szeto CC, Choi PC, et al: Isolate diffuse thickening of glomerular capillary basement membrane: A renal lesion in prediabetes? Mod Pathol 2004;17:1506-1512. (Pubitemid 39627077)
48. Succurro E, Arturi F, Lugará M, et al: Onehour postload plasma glucose levels are associated with kidney dysfunction. Clin J Am Soc Nephrol 2010;5:1922-1927.
49. Altiparmak MR, Pamuk ON, Pamuk GE, et al: Diffuse diabetic glomerulosclerosis in a patient with impaired glucose tolerance: Report on a patient who later develops diabetes mellitus. Neth J Med 2002;60:260-262. (Pubitemid 39089315)
50. Souraty P, Nast CC, Mehrotra R, et al: Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes. Nat Clin Pract Nephrol 2008;4:639-642.